BIOVIC B Share Price Performance
SEK 0.34
-1.51 (-81.76%)
88.8% undervalued intrinsic discount
SEK 3.00
Fair Value
Price SEK 0.34
AnalystHighTarget SEK 3.00
AnalystLowTarget SEK 0.60
AnalystConsensusTarget SEK 1.20
Fair ValueSEK 1.80
Share Pricen/a
Biovica International AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
BIOVIC B Community Narratives
AN
Fair Value SEK 1.8 81.3% undervalued intrinsic discount
Growing Cancer Incidence And AI Will Drive Diagnostic Expansion
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 0.6 43.8% undervalued intrinsic discount
Rising Reimbursement Cuts And Delays Will Weaken Market Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 1.2 71.9% undervalued intrinsic discount
Profitability Outlook Will Adjust Despite Stable Revenue And Equity Raise
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Growing Cancer Incidence And AI Will Drive Diagnostic Expansion
Key Takeaways Success in clinical trials and partnerships could accelerate adoption of DiviTum, driving rapid sales growth, recurring revenues, and higher gross margins through scalability and digital integration. Biovica's unique diagnostic position in value-based healthcare and precision oncology enhances its potential for durable premium pricing, industry consolidation, and attractiveness as an acquisition target.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 1.8
81.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
214.35% p.a.
Profit Margin
15.7%
Future PE
15.49x
Price in 2028
SEK 1.17
Profitability Outlook Will Adjust Despite Stable Revenue And Equity Raise
Key Takeaways Biovica's strategic partnerships and agreements are expected to expand market penetration, potentially boosting sales and future revenue growth. New clinical trial data and collaborations may enhance adoption of DiviTum, improving revenue streams and profit margins.Read more
42
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
SEK 1.2
71.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
197.79% p.a.
Profit Margin
1.25%
Future PE
43.01x
Price in 2028
SEK 1.39
Rising Reimbursement Cuts And Delays Will Weaken Market Prospects
Key Takeaways Heavy dependence on a single product and regulatory setbacks threaten Biovica's competitive edge, revenue growth, and earnings visibility. Increased cost containment, supply chain disruptions, and fierce competition limit pricing power and depress profitability.Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 0.6
43.8% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
219.06% p.a.
Profit Margin
21.33%
Future PE
3.18x
Price in 2028
SEK 1.54
Trending Discussion
Recently Updated Narratives
AN
BIOVIC B: U.S. Cancer Center Adoption Will Drive Future Biomarker Demand
Fair Value: SEK 1.8 81.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BIOVIC B: Future Returns Will Benefit From Advancing Breast Cancer Biomarker Evidence
Fair Value: SEK 1.2 71.9% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Reimbursement Cuts And Delays Will Weaken Market Prospects
Fair Value: SEK 0.6 43.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Biovica International AB (publ) Key Details
Last Reported Earnings
Oct 31, 2025
Next Reporting Earnings
Mar 18, 2026
- -0.26
- 100.96%
- -773.12%
- 0%
About BIOVIC B
- Founded
- 2008
- Employees
- 24
- CEO
- WebsiteView website
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
